What's Happening?
Skyhawk Therapeutics, a biotechnology company, has announced promising twelve-month interim results from its Phase 1/2 clinical trial of SKY-0515, an investigational treatment for Huntington's disease. The trial showed improvements in the Composite Unified
Huntington's Disease Rating Scale (cUHDRS) scores, with patients experiencing a mean increase of +0.38 points, compared to an expected decline of -0.92 points. Additionally, patients receiving a 9 mg dose of SKY-0515 achieved a 69% reduction in mutant huntingtin protein (mHTT), a key factor in Huntington's disease pathology. The study also reported that the Australia and New Zealand portion of the Phase 2/3 FALCON-HD pivotal study completed enrollment ahead of schedule, with 144 patients enrolled. The worldwide study has expanded to eight countries, with over 175 patients enrolled across the SKY-0515 Phase 1/2 and FALCON-HD pivotal studies.
Why It's Important?
The interim results from Skyhawk Therapeutics' trial are significant as they suggest a potential breakthrough in the treatment of Huntington's disease, a rare and fatal neurodegenerative disorder with no current therapies to slow or halt its progression. The reduction in mHTT protein and improvements in cUHDRS scores indicate that SKY-0515 could offer a new therapeutic option for patients, potentially altering the disease's trajectory. This development is crucial for the estimated 40,000 symptomatic individuals in the U.S. and hundreds of thousands worldwide affected by Huntington's disease. The success of SKY-0515 could also validate Skyhawk's SKYSTAR® platform, which aims to develop small molecule RNA-modulating therapies for various intractable diseases.
What's Next?
Skyhawk Therapeutics plans to continue advancing the development of SKY-0515, with the ongoing Phase 2/3 FALCON-HD pivotal program actively recruiting participants across more than 40 sites worldwide. The company aims to deliver an orally administered treatment that could transform the management of Huntington's disease. Further validation of the trial results in the Phase 2/3 study could lead to regulatory approval and commercialization, providing a much-needed treatment option for patients. Skyhawk also intends to expand its pipeline by advancing additional therapies targeting rare neurological diseases into clinical development by the end of 2027.
